What one share of Solid Biosciences holds
We are a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, which we refer to collectively as our Candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy (“Duchenne”), SGT-212 for the treatment of Friedreich’s ataxia (“FA”), SGT-501 for the treatment of Catecholaminergic polymorphic ventricular tachycardia (“CPVT”), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy (“TNNT2 DCM”), and…
Solid Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.87 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.70 |
| Cash and investments | $1.52 |
| Book value | $3.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$152.13 | $3.46 | −$181.10 | — | −$334.50 |
| 2017 | $0.00 | −$43.21 | $2.50 | −$50.00 | — | −$65.12 |
| 2018 | $0.00 | −$33.73 | $3.51 | −$35.16 | — | $53.00 |
| 2019 | $0.00 | −$43.64 | $1.63 | −$36.15 | — | $26.11 |
| 2020 | $0.00 | −$25.50 | $0.26 | −$16.61 | — | $23.34 |
| 2021 | $1.91 | −$10.14 | $0.18 | −$11.10 | — | $28.30 |
| 2022 | $0.95 | −$10.10 | $0.35 | −$11.86 | — | — |
| 2023 | — | −$4.83 | $0.08 | −$4.81 | — | $6.20 |
| 2024 | — | −$3.06 | $0.02 | −$2.47 | — | $3.39 |
| 2025 | — | −$1.99 | $0.01 | −$1.80 | — | $2.28 |
Common questions about Solid Biosciences
How much does one share of Solid Biosciences earn?
Over the last 12 months, Solid Biosciences lost $1.87 for each share.
Does Solid Biosciences pay a dividend?
Solid Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Solid Biosciences’s book value per share?
Solid Biosciences’s book value is $3.56 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Solid Biosciences have?
Each share of Solid Biosciences has $1.52 of cash and investments, as of June 30, 2026.
What is Solid Biosciences’s free cash flow per share?
−$1.70 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Solid Biosciences bought back shares?
Solid Biosciences’s share count rose about 77160% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.